mentorship of countless future leaders and service on the boards of organizations that strengthen Indiana's economy, environment, and civic life, demonstrates his lifelong dedication to service to our State.

For these reasons and more, Fred exemplifies what it means to be a Hoosier. It is my honor to recognize Fred for his distinguished career and congratulate him as he begins his retirement.●

MESSAGE FROM THE HOUSE

ENROLLED BILLS SIGNED

At 2:51 p.m., a message from the House of Representatives, delivered by Mrs. Cole, one of its reading clerks, announced that the Speaker has signed the following enrolled bills:

S. 195. An act to amend the Visit America Act to promote music tourism, and for other purposes.

S. 766. An act to require an annual report of taxpayer-funded projects that are over budget and behind schedule.

S. 2398. An act to reauthorize the Kay Hagan Tick Act, and for other purposes.

H.R. 5345. An act to amend title VII of the Social Security Act to provide for a single point of contact at the Social Security Administration for individuals who are victims of identity theft.

MEASURES PLACED ON THE CALENDAR

The following bill was read the second time, and placed on the calendar:

H.R. 9340. An act to amend the Public Utility Regulatory Policies Act of 1978 to establish a Federal standard relating to the recovery of the full, incremental costs of upgrades that serve large-load customers, and for other purposes.

EXECUTIVE AND OTHER COMMUNICATIONS

The following communications were laid before the Senate, together with accompanying papers, reports, and documents, and were referred as indicated:

EC–4794. A communication from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''Designation of Propionyl Chloride as a List I Chemical'' ((21 CFR Part 1310)(Docket No. DEA–1189)) received in the Office of the President of the Senate on September 23, 2026; to the Committee on the Judiciary.

EC–4795. A communication from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''Schedules of Controlled Substances: Placement of Diphenidine in Schedule I'' ((21 CFR Part 1308)(Docket No. DEA–1155)) received in the Office of the President of the Senate on September 23, 2026; to the Committee on the Judiciary.

EC–4796. A communication from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I'' ((21 CFR Part 1308)(Docket No. DEA–1146)) received in the Office of the President of the Senate on September 23, 2026; to the Committee on the Judiciary.

EC–4797. A communication from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''Ordering Schedule I and II Controlled Substances Using DEA Form 222; Technical Amendments'' ((21 CFR Part 1305)(Docket No. DEA–1005)) received in the Office of the President of the Senate on September 23, 2026; to the Committee on the Judiciary.

EC–4798. A communication from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act'' ((21 CFR Part 1308)(Docket No. DEA–989)) received in the Office of the President of the Senate on September 23, 2026; to the Committee on the Judiciary.

EC–4799. A communication from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''Schedules of Controlled Substances: Placement of CUMYL–PEGACLONE in Schedule I'' ((21 CFR Part 1308)(Docket No. DEA–1511)) received in the Office of the President of the Senate on September 23, 2026; to the Committee on the Judiciary.

EC–4800. A communication from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5, 6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act'' ((21 CFR Part 1308) (Docket No. DEA–1665)) received in the Office of the President of the Senate on September 23, 2026; to the Committee on the Judiciary.

EC–4801. A communication from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''Schedules of Controlled Substances: Removal of Exemption Status for Inactive Butalbital Products'' ((21 CFR Part 1308)(Docket No. DEA–1664)) received in the Office of the President of the Senate on September 23, 2026; to the Committee on the Judiciary.

EC–4802. A communication from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''Schedules of Controlled Substances: Rescheduling of Suvorexant, Lemborexant, and Daridorexant From Schedule IV Into Schedule V'' ((21 CFR Part 1308)(Docket No. DEA–1645)) received in the Office of the President of the Senate on September 23, 2026; to the Committee on the Judiciary.

EC–4803. A communication from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM–15, and MGM–16 in Schedule I'' ((21 CFR Part 1308)(Docket No. DEA–1644)) received in the Office of the President of the Senate on September 23, 2026; to the Committee on the Judiciary.

EC–4804. A communication from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I'' ((21 CFR Part 1308)(Docket No. DEA–1644)) received in the Office of the President of the Senate on September 23, 2026; to the Committee on the Judiciary.

EC–4805. A communication from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''Schedules of Controlled Substances: Temporary Placement of O–Desmethyltramadol in Schedule I'' ((21 CFR Part 1308)(Docket No. DEA–1641)) received in the Office of the President of the Senate on September 23, 2026; to the Committee on the Judiciary.

EC–4806. A communication from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance'' ((21 CFR Part 1308)(Docket No. DEA–1632)) received in the Office of the President of the Senate on September 23, 2026; to the Committee on the Judiciary.

EC–4807. A communication from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I'' ((21 CFR Part 1308)(Docket No. DEA–1604)) received in the Office of the President of the Senate on September 23, 2026; to the Committee on the Judiciary.

EC–4808. A communication from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''Schedules of Controlled Substances: Placement of Tianeptine in Schedule I'' ((21 CFR Part 1308)(Docket No. DEA–1596)) received in the Office of the President of the Senate on September 23, 2026; to the Committee on the Judiciary.

EC–4809. A communication from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''Schedules of Controlled Substance: Temporary Placement of 7-Hydroxy mitragynine Above a Specified Threshold in Schedule I'' ((21 CFR Part 1308)(Docket No. DEA–1570)) received in the Office of the President of the Senate on September 23, 2026; to the Committee on the Judiciary.

EC–4810. A communication from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I'' ((21 CFR Part 1308)(Docket No. DEA–1442)) received in the Office of the President of the Senate on September 23, 2026; to the Committee on the Judiciary.

EC–4811. A communication from the Acting Section Chief, Drug Enforcement Administration, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical'' ((21 CFR Part 1308)(Docket No. DEA–1427)) received in the Office of the President of the Senate on September 23, 2026; to the Committee on the Judiciary.

EC–4812. A communication from the Assistant General Counsel/Rules Administrator, Federal Bureau of Prisons, Department of Justice, transmitting, pursuant to law, the report of a rule entitled ''First Step Act Time Credits-Revisions'' (RIN1120–AB83) received in the Office of the President of the